Pfizer Inc. Q1 2008 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 30, 2008. Pfizer Inc. is a global, research-based pharmaceutical company operating primarily in two segments: Pharmaceutical and Animal Health. The company is currently navigating a changing business environment characterized by patent expirations on key products, increased generic competition, and ongoing cost-reduction initiatives.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Revenues | $11,848 million | $12,474 million |
| Net Income | $2,784 million | $3,392 million |
| Diluted EPS | $0.41 | $0.48 |
| Operating Cash Flow | $3,271 million | $1,243 million |
| Total Debt | $17,052 million | $13,139 million (Dec 31, 2007) |
| Cash & Short-term Investments | $28,628 million | $25,475 million (Dec 31, 2007) |
| Effective Tax Rate | 21.5% | 17.0% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 5% year-over-year. The Pharmaceutical segment declined 6% due to the loss of U.S. exclusivity for Norvasc, Zyrtec/Zyrtec D, and Camptosar, as well as competitive pressures on Lipitor. These declines were partially offset by growth in new products (Lyrica, Chantix, Sutent) and favorable foreign exchange impacts of approximately $570 million.
- Profitability: Net income decreased 18% to $2.78 billion. This was driven by higher acquisition-related in-process research and development (IPR&D) charges ($398 million vs. $283 million) and lower revenues, partially offset by significantly lower restructuring charges ($178 million vs. $812 million).
- Cost Structure: Cost of sales increased 5% while revenues fell, expanding the cost of sales margin from 15.1% to 16.8%. R&D expenses increased 8% due to higher implementation costs for cost-reduction initiatives.
- Liquidity: Net cash provided by operating activities increased significantly to $3.3 billion, primarily due to lower tax payments compared to the prior year. However, net cash used in investing activities was $5.5 billion, driven by net purchases of investments.
Guidance, Outlook, and Risks
2008 Full-Year Guidance:
- Revenues: $47.0 billion to $49.0 billion.
- Reported Diluted EPS: $1.73 to $1.88.
- Adjusted Diluted EPS: $2.35 to $2.45.
- Operating Cash Flow: $17 billion to $18 billion.
Management Commentary: Management expects to achieve a net reduction in pre-tax total expenses of $1.5 billion to $2.0 billion by the end of 2008 compared to 2006 levels, driven by cost-reduction initiatives including plant network optimization and sales force reductions.
Risks and Contingencies:
- Patent Litigation: Ongoing legal challenges regarding patents for Lipitor, Norvasc, Celebrex, and Detrol LA. While Pfizer has secured favorable rulings in some jurisdictions (e.g., Canada for Norvasc), reexamination proceedings continue in the U.S.
- Product Liability: Litigation regarding Mirapex (impulse-control disorders) and Celebrex/Bextra (safety concerns) remains active.
- Regulatory: Pending FDA approvals for several pipeline products (e.g., Fablyn, Zmax, Thelin) and potential labeling changes for Chantix regarding neuropsychiatric symptoms.
Investor Verification Checklist
- Verify the impact of generic competition on Lipitor sales trends in the U.S. versus international markets.
- Review the status of patent reexamination proceedings for Lipitor and the enantiomer patent with the U.S. Patent and Trademark Office.
- Assess the progress of cost-reduction initiatives against the target of $1.5–$2.0 billion in expense reductions by year-end 2008.
- Monitor the outcome of the proposed settlement in the Average Wholesale Price (AWP) litigation.
- Track the regulatory approval status of key pipeline candidates, specifically Thelin (PAH) and Fablyn (osteoporosis).